Result Filters
CADTH Canadian Drug Expert Committee recommendation (final). Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency.
- Author(s):
- CADTH Canadian Drug Expert Committee, author
- Canadian Agency for Drugs and Technologies in Health, issuing body
- Title(s):
- CADTH Canadian Drug Expert Committee recommendation (final). Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency.
- Other Title(s):
- Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency
Sebelipase alfa (Kanuma) - Series:
- CADTH common drug review
- Edition:
- Version 1.0.
- Country of Publication:
- Canada
- Publisher:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, September 28, 2018.
- Description:
- 1 online resource (1 PDF file (9 pages)).
-
Language:
- English
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK538940/
- MeSH:
- Cholesterol Ester Storage Disease/drug therapy*
Sterol Esterase/therapeutic use
- Notes:
- Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- Other ID:
- (OCoLC)1104457626
- NLM ID:
- 101745787 [Electronic Resource]